CLEVELAND, Nov. 11 /PRNewswire/ -- ChanTest, a leading provider of cardiac safety, ion channel, and GPCR services and products for drug discovery and development, today announced that Dr. F. John Mills and Joseph Gentile have been appointed to its board of directors. Dr. Mills is presently the CEO of BioStorage Technologies, Inc., which provides management, logistics, and biological specimens and data storage services for life sciences companies. Mr. Gentile is the former Vice President and General Manager of BD Biosciences Discovery Labware, where he helped to transform the business from a commodity lab plasticware supplier to a valued partner of researchers in life science and drug discovery.
Dr. Mills co-founded BioStorage Technologies in 2003, which currently serves over 100 life science companies worldwide. Dr. Mills previously held roles of increasing responsibility at Covance since 1991, most recently as the Corporate Senior Vice President and President, Clinical Support Services. In addition to Covance, he has held senior management positions at Corning and Janssen Pharmaceutical. Dr. Mills received his medical degree at Cambridge University, Pembroke College, a Ph.D. from the University of Surrey, and a Diploma in Pharmaceutical Medicine from the Royal College of Physicians, Edinburgh.
About ChanTest Corporation (www.chantest.com)
ChanTest’s mission is to serve the research, drug discovery and drug development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP), cell lines, membranes and reagents; the company’s library of validated ion channel cell lines is the most comprehensive, commercially available offering today. ChanTest’s pre-clinical cardiac risk assessment service portfolio is the most complete offering of its kind. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies. ChanTest works in partnership with customers to speed the drug development process, and ultimately to help make better, safer drugs. Because of ChanTest’s seminal role in the pre-clinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.
ChanTest Corporation
